A Study to Investigate the Effect of Linaprazan Glurate on the Pharmacokinetics of Amoxicillin

NCT ID: NCT07308041

Last Updated: 2025-12-29

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE1
• Total Enrollment: 12 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-11-11
• Study Completion Date: 2025-12-22

Brief Summary

This is an open, single arm, single-center Phase I trial designed to evaluate the effect of seven days repeated oral doses of linaprazan glurate on the pharmacokinetics (PK) of repeated doses of amoxicillin in healthy male and female participants

Detailed Description

Participants in the trial will attend three visits to the clinical research unit (CRU) and a telephone follow-up visit.

Eligible participants will be admitted to the CRU in the evening of Day -1 and will remain at the CRU until the morning of Day 2 In the morning of Day 1, after pre-dose assessments, a dose of amoxicillin will be administered followed by 24 hours PK blood sampling for determination of amoxicillin plasma concentrations. Safety will be followed up throughout the 24 hours. In the morning of Day 2, after the 24-hour amoxicillin PK sample and safety assessments, the first linaprazan glurate will be administered to the participants. The participants will then continue to take linaprazan glurate (Day 2 to Day 8).

The participants will be admitted to the CRU in the afternoon of Day 6 and will remain at the CRU until the morning of Day 9. PK samples for determination of linaprazan glurate and linaprazan in plasma will be collected for 24 hours at Day 7. In the morning of Day 8, the participants will be administered a new dose of amoxicillin together with the dose of linaprazan glurate, which will be followed by 24 hours PK sampling for determination of amoxicillin, linaprazan glurate and linaprazan plasma concentrations. The participants will leave the CRU after the 24-hour PK sample and safety assessments.

A final end-of-trial telephone call will take place seven days (±two days) after the final dosing on Day 8.

Conditions

Drug Interaction; GERD (Gastroesophageal Reflux Disease); Safety, and Tolerability

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Linaprazan glurate

Oral administration for seven (7) days.

Group Type: EXPERIMENTAL

Drug Drug Interaction

Intervention Type: DRUG

The intervention phase consists of 2 periods: in period 1, the pharmacokinetics (PK) of amoxicillin will be evaluated in the absence of linaprazan glurate, in period 2, a potential effect of linaprazan glurate on the PK of amoxicillin will be evaluated as well as the PK of linaprazan glurate following co-administration of amoxicillin.

Interventions

Drug Drug Interaction

The intervention phase consists of 2 periods: in period 1, the pharmacokinetics (PK) of amoxicillin will be evaluated in the absence of linaprazan glurate, in period 2, a potential effect of linaprazan glurate on the PK of amoxicillin will be evaluated as well as the PK of linaprazan glurate following co-administration of amoxicillin.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Willing and able to give written informed consent for participation in the trial.
• Healthy male or female participant aged 18 to 64 years, inclusive.
• Body mass index (BMI) ≥ 18.5 and ≤ 30.0 kg/m2 at the time of the screening visit.
• Medically healthy participant without abnormal clinically significant medical history, physical findings, vital signs, ECG and laboratory values at the time of the screening visit, as judged by the Investigator.

Exclusion Criteria

• Female participants of childbearing potential (defined as all participants physiologically capable of becoming pregnant) unless they agree to use one of the following highly effective methods of contraception (failure rate of <1%) from 2 weeks prior to the first dose until the end-of-trial visit:

• Sterilization of a male partner, defined as vasectomy, at least six months prior to screening.
• Intra-uterine device (non-hormonal or copper IUD).
• Double-barrier methods of contraception, i.e., condoms in combination with occlusive cap with contraceptive gel.
• Male participants with a partner of childbearing potential, unless they agree to use one of the following methods of contraception from two weeks prior to the first dose until the end-of-trial visit:

• Vasectomy at least six months prior to screening.
• Condoms. Female partners of childbearing potential must then agree to concurrently use a highly effective method of contraception.
• History of any clinically significant disease or disorder which, in the opinion of the Investigator, may either put the participant at risk because of participation in the trial, or influence the results or the participant's ability to participate in the trial.
• Any clinically significant illness, medical/surgical procedure or trauma within four weeks of the first administration of IMP.
• Positive result for H.pylori antibodies at the time of the screening visit.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 64 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Cinclus Pharma Holding AB

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

CTC Clinical Trial Consultants AB

Uppsala, , Sweden

Site Status: RECRUITING

Countries

Sweden

Central Contacts

Sophie Leyman, MD

Role: CONTACT

Phone: +32470214020

Email: sophie.leyman@cincluspharma.com

Kajsa Larsson, MD, PhD

Role: CONTACT

Email: kajsa.larsson@cincluspharma.com

Facility Contacts

Måns Jergil, PhD

Role: primary

Other Identifiers

CX842B2111

Identifier Type: -

Identifier Source: org_study_id